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Background. Probiotics are proposed to positively modulate the intestinal epithelial barrier formed by intestinal epithelial
cells (IECs) and intercellular junctions. Disruption of this border alters paracellular permeability and is a key mechanism for the
development of enteric infections and inflammatory bowel diseases (IBDs). Methodology and Principal Findings. To study
the in vivo effect of probiotic Escherichia coli Nissle 1917 (EcN) on the stabilization of the intestinal barrier under healthy
conditions, germfree mice were colonized with EcN or K12 E. coli strain MG1655. IECs were isolated and analyzed for gene and
protein expression of the tight junction molecules ZO-1 and ZO-2. Then, in order to analyze beneficial effects of EcN under
inflammatory conditions, the probiotic was orally administered to BALB/c mice with acute dextran sodium sulfate (DSS)
induced colitis. Colonization of gnotobiotic mice with EcN resulted in an up-regulation of ZO-1 in IECs at both mRNA and
protein levels. EcN administration to DSS-treated mice reduced the loss of body weight and colon shortening. In addition,
infiltration of the colon with leukocytes was ameliorated in EcN inoculated mice. Acute DSS colitis did not result in an anion
secretory defect, but abrogated the sodium absorptive function of the mucosa. Additionally, intestinal barrier function was
severely affected as evidenced by a strong increase in the mucosal uptake of Evans blue in vivo. Concomitant administration of
EcN to DSS treated animals resulted in a significant protection against intestinal barrier dysfunction and IECs isolated from
these mice exhibited a more pronounced expression of ZO-1. Conclusion and Significance. This study convincingly
demonstrates that probiotic EcN is able to mediate up-regulation of ZO-1 expression in murine IECs and confer protection from
the DSS colitis-associated increase in mucosal permeability to luminal substances.
Citation: Ukena SN, Singh A, Dringenberg U, Engelhardt R, Seidler U, et al (2007) Probiotic Escherichia coli Nissle 1917 Inhibits Leaky Gut by Enhancing
Mucosal Integrity. PLoS ONE 2(12): e1308. doi:10.1371/journal.pone.0001308
INTRODUCTION
The epithelial layer of the gastrointestinal tract serves as one of the
primary interfaces with the outside world. The mucosal surface of
the intestinal epithelium is in constant contact with abundant
populations of microbes and their metabolites. The intestinal
barrier formed by the epithelial cells and the junctional complex,
consisting of tight junctions (TJ), adherens junctions, gap junctions
and desmosomes, excludes the majority of these microbes and
their metabolites from access to the subepithelial cells. Its
effectiveness and stability are ensured by the junctional complex
[1]. Compromising the integrity of this barrier can promote
manifestation of enteric infections and is a key feature of IBDs like
Crohn’s disease (CD) and ulcerative colitis (UC). Intestinal
permeability was also found to be increased in HIV infection
[2], and diarrhea is one of the most predominant symptoms of
HIV-infected patients. The diarrhea of these patients is mainly due
to infections with enteropathogens. However, in a number of HIV
patients with gastrointestinal complaints no enteropathogen can be
identified [3,4]. The role of a ‘leaky gut’ in the pathogenesis of
gastrointestinal diseases is increasingly recognized. Consequently,
reduction of the increased permeability is an interesting target for
improvement of the clinical status of gastrointestinal diseases.
Tight junctions are intricate macromolecular protein structures
located at the most apical regions of the junctional complex,
sealing the spaces between the IECs. The first junction-associated
protein identified was zonula occludens 1 (ZO-1), with a molecular
mass between ,210–225 kDa [5]. This molecule constitutes the
structural link between the cytoskeleton and the tight junction by
binding to both actin filaments and the TJ protein occludin [6].
Reorganization of TJ proteins like ZO-1, triggered by cytokines
producedsecondarytotheinflammatoryprocessesinIBDs,resultsin
increasedintestinalpermeability[7,8].ZO-2isanotherTJassociated
protein that forms a complex together with ZO-1 [9] and has
recently been shown to be up-regulated by EcN in vitro [10].
Probiotics are defined as live microorganisms which, when
administered in adequate amounts, confer health benefits to the
host [11]. The use of such microorganisms as novel therapeutic
agents and as an alternative to standard medication in gastroin-
testinal diseases is promising, although their mechanism of action
is still under investigation. EcN has evolved into one of the best
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have convincingly been proven [12–16]. A potential mechanism
by which probiotics may exhibit their beneficial activities is
modulation of the epithelial barrier function [17,18]. This
hypothesis is also supported by a recent study demonstrating that
probiotic Streptococcus thermophilus and Lactobacillus acidophilus can
prevent invasion of enteroinvasive E. coli and enhance intestinal
epithelial barrier function by amplifying phosphorylation of
occludin and ZO-1 in vitro [19].
Driven by mounting evidence affirming the beneficial effects of
probiotics on the intestinal epithelial barrier and the already well-
documentedtherapeutic efficacyof EcN,we set out to investigate the
impact of EcN on the intestinal epithelial barrier function in vivo.
MATERIALS AND METHODS
Mice
All mice used in this study were 6–8 weeks old females.
Conventional BALB/c mice were obtained from Harlan (Borchen,
Germany). Gnotobiotic BALB/c mice were obtained from colonies
maintained germfree at the Central Animal Facility of Hannover
Medical School, as described previously [20]. The animal
experiments reported here were conducted in accordance with the
German Animal Welfare Law and with the European Communities
Council Directive 86/609/EEC for the protection of animals used
for experimental purposes. All experiments were approved by the
local institutional animal care and research advisory committee and
authorized by the district authority of Braunschweig and Hannover.
Bacterial colonization of gnotobiotic BALB/c mice
EcN or E. coli MG1655 was freshly grown to an OD600=1(,0.8–
1.2610
9 CFU/ml) from an overnight culture diluted 1:500 in LB
media [21].Bacteria were collectedbycentrifugation (1 ml, 3 min at
10006g). The resulting pellet was redissolved in 200 ml sterile PBS
and administered by oral gavage. Application was repeated two days
later. After 6 days of colonization, fecal CFU were determined by
plate count from pooled stool samples and were calculated per gram
feces. The animals grew comparable numbers of both bacterial
strains in all experiments averaging 5.8610
9 CFU/g feces with EcN
and 5.1610
9 CFU/g feces with E. coli MG1655. Feces of mice that
had received PBS remained sterile.
Induction of colitis
Acute colitis was induced in BALB/c mice by addition of 4–6%
dextran sodium sulfate (DSS) (MP Biomedicals, Eschwege,
Germany) to drinking water for a period of 8 days, according to
a protocol recently described by Grabig et al. [22]. Animals were
separated into the following groups: Group I was treated orally
with PBS two times a day. Group II received drinking water with
4–6% DSS and was treated orally with PBS twice daily. Group III
also received drinking water with 4–6% DSS and was given 1.5–
2610
8 CFU (Mutaflor mite, Ardeypharm, Germany) EcN twice
daily by oral application (DSS+EcN) (Figure 1). Colitis induction
indicated by weight loss of the mice was monitored by comparing
the body weight upon DSS treatment to the initial body weight of
the respective animals.
Isolation of IECs
IECs were isolated as described elsewhere [23]. Briefly, the small
and/or large intestine were isolated, rinsed with PBS and opened
longitudinally. Mucus was removed by treatment with DTT for
15 min at 37uC on a shaker. Having washed the mucosa in PBS, it
was placed in HBSS/1.5 mM EDTA and tumbled for 10 min at
37uC. The supernatant was collected and the remaining mucosa
was vortexed in PBS. This supernatant was also collected. Pooled
IECs were centrifuged with HBSS/PBS; the pellet was resus-
pended in FACS buffer (PBS+2% FCS+2 mM EDTA) and stained
with anti-CD45 APC antibody (BD Biosciences, Heidelberg,
Germany) to deplete hematopoietic cells [24]. IECs were sorted
with a MoFlow cell sorter (Cytomation, Fort Collins, CO, USA).
RNA isolation and expression analysis
To analyze ZO-1 and ZO-2 mRNA expression in murine IECs,
total RNA was isolated using the RNeasy Minikit (Qiagen, Hilden,
Germany) with on-column DNase digestion using the RNase-Free
DNase set (Qiagen). Isolated mRNA was reverse transcribed with
200 U Superscript IIH (Invitrogen, Karlsruhe, Germany), oligo
dT- and random hexamer primers (Invitrogen). PCR was
performed using the following primers: ribosomal protein 9
(RPS9) mouse (mm) sense primer CTG GAC GAG GGC AAG
ATG AAG C, RPS9 mm anti-sense primer TGA CGT TGG
CGG ATG AGC ACA; ZO-1 mm sense primer TTT TTG ACA
GGG GGA GTG G, ZO-1 mm anti-sense primer TGC TGC
AGA GGT CAA AGT TCA AG; ZO-2 mm sense primer CTA
GAC CCC CAG AGC CCC AGA AA, ZO-2 mm anti-sense
primer TCG CAG GAG TCC ACG CAT ACA AG. Quantitative
real-time RT-PCR was done with the GeneAmp 5700 Sequence
Detection System (Perkin Elmer, Rodgau-Ju ¨gesheim, Germany)
using Brilliant SYBR Green QPCR Core Reagent Kit (Stratagene,
Heidelberg, Germany). RPS9 served as control.
Western blot analysis
To examine the ZO-1 protein expression in IECs, lysates of sorted
cells from colonized gnotobiotic mice were homogenized and
Figure 1. Experimental design of the DSS colitis model. Acute colitis was induced by administration of 4–6% DSS to drinking water (DSS). (A) Group
I was orally treated with PBS twice daily. Group II was given 4–6% DSS in drinking water and orally treated with PBS twice daily. Group III received 1.5–
2610
8 CFU EcN two times a day by oral application in combination with 4–6% DSS in drinking water (DSS+EcN).
doi:10.1371/journal.pone.0001308.g001
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phoresis (SDS–PAGE), followed by blotting the proteins on a
PVDF membrane. After the blocking of unsaturated protein
binding sites, the membrane was incubated with the primary
antibody rabbit anti-ZO-1 (Zymed, South San Francisco, CA,
USA) or rabbit anti-b actin (Sigma-Aldrich, Taufkirchen,
Germany) and the secondary antibody goat anti-rabbit IgG
(Dianova, Hamburg, Germany), respectively.
Electricphysiologic measurements
The colonic mucosa was mounted between two chambers with an
exposed area of 0.625 cm
2 and placed in an Ussing chamber.
Parafilm ‘‘O’’ rings were used to minimize edge damage to the
tissue where it was secured between the chamber halves. Tissues
were bathed with HCO3
2 containing solutions on both sides
which were gassed with 95% O2/5% CO2. The composition (in
mM) was 108 NaCl, 22 NaHCO3, 3 KCl, 1.3 MgSO4, 2 CaCl2,
1.5 KH2PO4, at pH 7.4. The serosal bath contained (in mM) 8.9
glucose, 10 sodium pyruvate, 10
23 indomethacin, and 10
23
tetrodotoxin; the luminal bath contained 8.9 mannitol and 10
22
amiloride (to block potential amiloride-sensitive Na
+ channels).
Short-circuit current (Isc), potential difference (PD) and tissue
resistance (R) were recorded using the Mussler 6-channel voltage
clamp system (Mussler, Aachen, Germany).
22Na
+ studies were
performed during voltage clamp to zero PD. 74 kBq/ml
22Na
+
was added to either the serosal or the mucosal solution after
reaching stable electrical parameters. After stabilization (approx-
imately 20–30 minutes after mounting), a 45-minute period of
equilibration followed, then aliquots were taken in 15-minute
intervals (two intervals for basal flux, two after forskolin, and two
after luminal glucose). For the presented results, we used the
values from the second basal flux period, the first period after
forskolin, and the first period after glucose. There were no
statistically significant differences between the values obtained in
the first and second flux period after forskolin and after glucose.
Radioactivity was determined in a liquid scintillation counter, and
bidirectional flux rates for the respective substance were
calculated. The values for Isc represent the average value of the
15-minute period.
Measurement of colonic epithelial permeability
Animals were maintained with free access to food and water.
Induction of anesthesia was achieved by the administration of
10 ml/g intraperitoneal haloperidol/midazolam/fentanyl cocktail
(haloperidol 12.5 mg/kg, fentanyl 0.325 mg/kg and midazolam
5 mg/kg body weight). The lower abdomen was opened by one
small central incision, and a small polyethylene tube (PE100) with
a distal flange was advanced to the proximal colon (immediately
after the cecum), and secured by a ligature that served as inlet
tube. A PE200 flanged tubing was inserted through the rectum
and secured by ligature to allow for drainage through the rectum.
The isolated colon segment with an intact blood supply was gently
flushed and then perfused (Perfusor compact, BRAUN, Melsun-
gen, Germany) at a rate of 30 ml/h with 150 mmol/l NaCl for
5 min, followed by perfusion with 1% Evans Blue in NaCl for
10 min. To wash-out the sticking dye in the mucus, the lumen was
perfused with 6 mM acetylcysteine for 5 min followed by NaCl for
10 min. The animals were then sacrificed by cervical dislocation
and the ligated colon was removed. The colon was rinsed once
more with saline, its length was recorded and it was then placed in
5 ml N,N- dimethyl-formamide overnight to extract the Evans
Blue. The dye concentration was measured spectrophotometrically
at 620 nm (Hitachi U-2000 UV/VIS, Hitachi, Japan).
Immunofluorescence
Tissue sections were fixed with 4% paraformaldehyde, washed
extensively and blocked with porcine serum. Subsequently, the
sections were incubated with the primary antibody rabbit anti-
ZO-1 (Zymed) followed by incubation with a Cy3 labeled
secondary goat anti-rabbit IgG antibody (Jackson Immunore-
search, Cambridgeshire, UK). The sections were then dried,
covered with gelatine and visualized by fluorescence microscopy.
Statistical analysis
Statistical analysis was performed with Origin 7.5 software
(OriginLab, Northampton, MA, USA). For analysis of numeric
values, the one-tailed analysis of variance and the Student’s t-test
were used. A p-value of ,0.05 was considered significant. Error
bars represent the standard error of the mean.
RESULTS
ZO-1 mRNA and protein expression are elevated in
gnotobiotic mice colonized with EcN
In order to investigate the impact of a single bacterial species on
host IEC gene expression, we established a model for colonization
of gnotobiotic mice with EcN and E. coli MG1655. To further
investigate the in vivo impact of EcN on the epithelial barrier,
primary IECs from the intestine of gnotobiotic mice were isolated
and sorted by FACS resulting in an IEC population with greater
than 94% purity (Figure 2A). ZO-1 is a TJ protein which has been
described to play an important role in the prevention of intestinal
barrier disruption by probiotics. Therefore, we investigated
whether EcN differentially regulates ZO-1 mRNA expression in
vivo. As depicted in figure 2B colonization of gnotobiotic mice with
EcN resulted in a specific up-regulation of ZO-1 mRNA in IECs
(p,0.05). To confirm these data at protein level, sections of ileum
and colon from gnotobiotic control mice and animals colonized with
EcN were stained with anti-ZO-1 antibody followed by a
fluorescence-labeled secondary antibody (Figure 3A). Comparison
of ZO-1 staining along the surface of the crypts revealed only a slight
increase of ZO-1 protein in IECs of mice colonized with EcN. To
further analyze the up-regulated ZO-1 expression at protein level,
isolated IECs were investigated by Western blotting. In comparison
to IECs isolated from control mice and those colonized with E. coli
MG1655, IECs from EcN treated animals showed a markedly
elevated expression of ZO-1 protein (Figure 3B). Thus, we could
clearly demonstrate that colonization of gnotobiotic mice with EcN
specifically up-regulates ZO-1 expression at the mRNA as well as at
the proteinlevel.Due totheimportant functional roleof ZO-1 inthe
junctional complex, these findings suggest that enhancement of the
intestinal epithelial barrier function by EcN could at least in part be
attributed to up-regulation of ZO-1. It has also been previously
demonstrated that treatment of T84 cells with EcN leads to an up-
regulationofZO-2invitro[10].Incontrasttothedatageneratedwith
the T84 cell line, analysis of ZO-2 mRNA expression in IECs
isolated from gnotobiotic mice colonized with EcN or E. coli
MG1655 did not result in an increase of ZO-2 mRNA levels (fold
change ,2) in vivo (Figure 2C).
Elevated ZO-1 expression after EcN treatment in
experimental colitis
It has been shown that the impaired barrier function in IBD is
associated with an altered TJ structure [7,8,25–28]. Recently it
was demonstrated that EcN, used as a therapeutic for the
treatment of ulcerative colitis, ameliorates acute colitis in mice
[29]. These observations raised the question whether an alleviated
EcN Inhibits Leaky Gut
PLoS ONE | www.plosone.org 3 December 2007 | Issue 12 | e1308acute colitis-as a consequence of EcN treatment-may be due to its
effect on the epithelial barrier. To investigate this aspect acute
colitis was induced in BALB/c mice by administration of 4–6%
DSS in drinking water for a period of 8 days [22]. In addition,
mice were given 1.5–2610
8 CFU EcN or PBS orally two times a
day. In contrast to untreated control mice of group I, mice
exposed to DSS (group II) developed symptoms of acute colitis
with diarrhea, rectal bleeding and wasting, loosing 10% of their
initial body weight within 8 days (Figure 4A). Concomitant oral
administration of EcN (group III) significantly ameliorated the
severity of DSS-induced colitis and the loss of body weight was
reduced (6%) (p,0.05). Healthy control mice (group I) exhibited
an average colon length of 8.4 (61.1) cm, whereas, as a
consequence of severe intestinal inflammation, the colon length
of DSS treated diseased mice (group II) was reduced to 6.9 (61.2)
cm (p,0.001). In contrast, in DSS and EcN treated mice (group
III), this colon shortening was significantly attenuated with 7.5
(61.5) cm (p,0.05) (Figure 4B). Colonic inflammation is
correlated with strong infiltration of hematopoietic cells into the
intestine. To further elaborate the beneficial effect of EcN in DSS
treated mice, FACS analysis of hematopoietic cells in the colon
was performed. Consistent with the reduction in loss of body
weight and colon shortening, mice treated with DSS and EcN
(group III) exhibited significantly lower leukocyte infiltrates in the
colon in comparison to DSS treated mice (group II) (Figure 4C).
To analyze whether the improved state of health after EcN
treatment is accompanied with an increased ZO-1 expression,
IECs were isolated from the colon of treated mice and analyzed for
ZO-1 gene expression. IECs of mice treated with DSS and EcN
showed elevated ZO-1 mRNA levels in comparison to DSS
treated animals (p,0.05) (Figure 5). Although ZO-2 mRNA was
not up-regulated by EcN under healthy conditions, a slight
Figure 2. Isolation of IECs from gnotobiotic mice colonized with EcN or E. coli MG1655 and ZO-1 expression analysis. Gnotobiotic BALB/c mice
were colonized with E. coli MG1655 (K12) or EcN for 6 days, respectively. Application of PBS was used as control. (A) Whole intestinal cell populations
were isolated from gnotobiotic mice treated either with PBS, K12 or EcN. For sorting of a pure intestinal epithelial cell population, cells were labeled
with anti-CD45 antibody to exclude hematopoietic cells and further distinguished by cell granularity and size (SSC) (Pre sorting). IECs were FACS-
sorted by negative selection. Re-analysis was performed to determine the purity of sorted IECs (Post sorting). (B) Quantitative ZO-1 mRNA expression
in IECs. Relative mRNA amounts were normalized with respect to expression levels of IECs from control mice (fold change=1). Data are presented as
mean of three independent experiments (n=3/group). (C) Quantitative ZO-2 mRNA expression in IECs. Relative mRNA amounts were normalized with
respect to expression levels of IECs from control mice (fold change=1). Data are presented as mean of three independent experiments (n=3/group).
*p,0.05 EcN vs. Ctrl (relative expression values).
doi:10.1371/journal.pone.0001308.g002
Figure 3. ZO-1 protein expression in ileum and colon of gnotobiotic
mice. (A) Immunofluorescence staining of tissue sections from gnotobi-
otic control mice and mice colonized with EcN for 6 days with a
fluorescent anti-ZO-1 antibody (orange). Original magnification620. (B)
Protein expression of ZO-1 in IECs. Western blot analysis of FACS sorted
IECs from colonized mice was performed using anti-ZO-1 antibody. Anti-b
actin antibody was used as internal control, binding to the corresponding
protein with a molecular weight of 42 kDa. The ZO-1 antibody detects
endogenous ZO-1 protein, displayed as a band at ,210 kDa.
doi:10.1371/journal.pone.0001308.g003
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with EcN (data not shown). These results further underline the
beneficial effects of EcN on the intestinal barrier even under
inflammatory conditions.
Electrolyte transport capacity and tissue resistance
after EcN treatment in experimental colitis
In order to assess the electrolyte transport capacity and the tissue
resistance (R) in acute DSS colitis, and the influence of EcN
treatment on these parameters, the basal and forskolin-stimulated
Isc, basal and forskolin-inhibited Na
+ absorption, and the tissue-
resistance R in isolated colonic mucosa of inflamed DSS treated
mice (group II), DSS and EcN treated mice (group III), and
healthy controls (group I) were studied. To ensure that any
potential inflammation-related changes would be detected, the
mucosa was neither stripped nor were the prostaglandin
production or neural transmission inhibited. Interestingly, no
difference was found in either the basal and forskolin-stimulated
Isc (Figure 6A), or in the transmucosal electrical resistance (R)
Figure 4. Administration of EcN in DSS induced colitis. (A) Disease severity was measured daily and is expressed in terms of body weight loss.
(group II: n=23, group III: n=25, group I: n=17) *p,0.05 group III vs. group II. (B) Reduction of colon length. Measurement of colon length [cm] after
preparation. (group II: n=24, group III: n=25, group I: n=13) *p,0.05 group III vs. group II or group III vs. group I **p,0.01 group II vs. group I. (C)
Infiltration of hematopoietic cells into the colon. Whole intestinal cell populations were labeled with anti-CD45 APC antibody and measured by FACS
analysis (n=6/group).
doi:10.1371/journal.pone.0001308.g004
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that in acute DSS colitis, the anion secretory capacity, which
originates from the cryptal region of the colonic epithelium, is not
perturbed. On the other hand, net Na
+ absorption was
significantly decreased in colonic mucosa of DSS and EcN treated
mice (group III), and reversed to Na
+ leakage into the luminal fluid
in the mucosa of DSS treated mice (group II) (Figure 6B). Since
the transporters for Na
+ absorption are expressed in the surface
colonic enterocytes, this demonstrates severe alterations in surface
cell electrolyte transport following treatment with EcN.
Reduction of colonic epithelial permeability after
EcN treatment in experimental colitis
In order to address the question whether the pronounced ZO-1
expression in EcN treated mice (group III) impacts the
permeability of the colonic epithelium for transport of luminal
substances, the uptake of Evans Blue into the mucosa in
anesthetized mice after a short-term luminal perfusion with the
dye was measured. In comparison to untreated mice (group I), a
strong increase of Evans Blue uptake into the colonic mucosa of
DSS treated mice (group II), and a much lesser increase into the
colonic mucosa of DSS and EcN treated mice (group III) was
detected (Figure 7). This demonstrates that the concomitant
application of EcN during colitis induction with DSS markedly
ameliorates the leakiness of the colonic epithelium.
DISCUSSION
The current study establishes that E. coli Nissle 1917 positively
impacts the intestinal epithelial barrier in vivo in three different
ways. First, EcN is capable of producing a specific up-regulation of
ZO-1 expression in IECs of healthy gnotobiotic mice. When
treated concomitantly with EcN, IECs of mice with DSS-induced
colitis also exhibit a pronounced expression of ZO-1 mRNA.
Finally, EcN provides protection against the DSS-mediated
leakiness of the gut in our mouse model. Our data strongly
suggest that one of the protective effects of EcN treatment on
colitis prevention could be a modulation of tight junctional
integrity which in turn leads to preserved intestinal barrier
function against noxious or infectious agents.
Critical for the development of IBDs are imbalances in mucosal
immunity as well as a disturbed function of the epithelial barrier,
which leads to a marked infiltration of luminal microflora [30].
Moreover, in the majority of cases, gastrointestinal diseases
develop from the disruption of the intestinal epithelial barrier by
enteropathogenic bacteria that alter the cellular cytoskeleton
[31,32] or affect specific tight junction proteins like ZO-1 [33]. In
the past years, probiotics have been shown to be effective in the
treatment of mild to moderately active IBD [18] and to reduce
inflammation in animal models of colitis [29,34–36]. Three large
clinical trials have investigated the therapeutic efficacy of EcN in
maintaining remission of UC. EcN was reported to be as
efficacious as standard medication in preventing the relapse of
UC [12–14]. Although the mechanisms leading to relapses in the
pathogenesis of IBDs have not yet been clarified, there is growing
evidence that increased intestinal permeability plays a key role.
This report is the first to demonstrate a direct influence of the
therapeutic EcN on expression of the TJ associated molecule ZO-1
in vivo under healthy and inflammatory conditions. We demon-
strate that EcN specifically up-regulates ZO-1 expression both at
the mRNA and at the protein level in IECs of gnotobiotic mice.
Very recently, Zyrek et al. described the up-regulation of ZO-2
after EcN exposure to the T84 cell line in vitro [10]. However, in
this study analysis of IECs from gnotobiotic mice colonized with
EcN did not reveal a differential ZO-2 mRNA expression in vivo
following EcN treatment.
In order to study functional consequences of DSS-mediated
colitis and EcN treatment and also the potential significance of
ZO-1 up-regulation for an enhancement of intestinal barrier
function, we performed experiments aimed to assess transport and
barrier function of the colonic epithelium of DSS-treated mice
with and without application of EcN. To evaluate secretory and
absorptive function of the colonic epithelium, we measured the
basal and forskolin-stimulated Isc (which is an assessment of the
electrogenic anion secretion, and its stimulation by an increase in
intracellular cAMP levels), as well as net Na
+ absorption before
and after an increase in cAMP levels. Interestingly, after one week
of DSS treatment, the acute colitis did not compromise the
secretory function of the epithelium at all, but abolished the Na
+
absorptive function completely. Na
+ absorption is mediated by
electroneutral (apical Na
+/H
+ exchangers NHE3 and possibly
NHE2) and electrogenic (apical Na
+ channel ENaC) pathways in
the colon [37]. Na
+ absorptive transporters are compromised
during acute colitis, and this is one major reason for diarrhea
during colonic inflammation [38].
Active fluid absorption is also dependent on intact tight
junctions, otherwise a phenomenon called ‘‘leak flux diarrhea’’
occurs [39–41]. A cytokine-induced intestinal barrier dysfunction
via a leak flux mechanism has recently been proposed by Schmitz
et al. as potential cause for non-infectious diarrhea in HIV-
infected patients, in addition to mucosal transformation with a
consecutive malabsorptive mechanism [42]. When cholera toxin
deletion mutants of Vibrio cholerae were given to healthy volunteers
they still developed mild diarrhea [43]. Searching for the causative
agent led to the detection of the ZOT, a toxin which causes a
disruption of the tight junctions in isolated intestine [44]. Later
studies revealed yet another agent from Vibrio cholerae, the HA/
protease, that specifically interferes with the tight junction proteins
occludin and ZO-1 resulting in barrier disruption [45,46]. Thus, it
became clear that the integrity of the tight junctions was necessary
for the maintenance of an absorptive state of the gut epithelium. In
addition, it was found that a disruption of the tight junctional
complex allowed easier permeation of substances from the lumen
[47]. Our experiments demonstrated a strongly elevated influx of
Evans Blue into the colonic mucosa in the live mouse with DSS
colitis which is indicative of increased gut permeability. Much less
dye was bound to IECs of mice treated concomitantly with EcN.
Combined with the absorptive Na
+ flux in these animals, this is
likely to explain the nearly normal appearance of the feces in the
Figure 5. Increased ZO-1 mRNA expression in mice treated with DSS
and EcN. IECs were isolated from indicated mice and relative levels of
ZO-1 mRNA were normalized with respect to the expression level of
IECs from DSS treated mice (fold change=1). Data are presented as
mean of four independent experiments (n=3/group). *p,0.05 group III
vs. group II (relative expression values).
doi:10.1371/journal.pone.0001308.g005
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mice with DSS colitis. It is feasible that the reduction of DSS-
mediated downregulation of ZO-1 expression by EcN treatment is
one reason for the enhanced barrier stability.
Several lines of evidence suggest that increased intestinal
permeability has a central role in the pathogenesis of IBDs. For
example, between 10–20% of presymptomatic CD patients have
been shown to exhibit increased gut permeability [48,49].
Alteration of TJ structure in UC for instance results in impaired
barrier function [40]. Localization studies in mucosal biopsies of
IBD patients have revealed disappearance of key TJ proteins from
intercellular junctions [26,50]. Probiotics have been shown to
reduce the increased intestinal permeability in vitro [51] as well as
in clinical trials [52]. Here we demonstrate for the first time that
the substantially increased intestinal permeability of mice treated
with DSS is significantly alleviated by simultaneous oral
application of EcN. In addition, we observed an altered ZO-1
expression profile in IECs of mice with DSS-induced colitis.
Recently, a study described the translocation of ZO-1 from the
apical to the basolateral side in CD patients [53] indicating an
alteration of ZO-1 under pathological conditions. Moreover, using
a mouse colitis model, Resta-Lenert et al. have shown that the
increase in intestinal permeability is associated with a decrease of
occludin and ZO-1 phosphorylation [54].
However, administration of EcN in our mouse models not only
diminished the clinical signs of colitis like colon shortening and
weight loss, but also prevented an increase in intestinal
permeability while concurrently minimizing the down-regulation
of IEC ZO-1 expression. This indicates a considerable association
between the severity of colitis, as evidenced by increased gut
Figure 6. Secretory and absorptive function of isolated colonic mucosa from DSS-treated mice, with and without EcN administration, and
healthy controls. (A) Basal and forskolin-stimulated Isc in DSS treated (group II n=7), DSS+EcN (group III n=12) and control animals (group I n=10).
The different numbers resulted from the fact that considerably more colonic segments from the DSS treated mice were so friable that they ruptured
before measurements could be taken. (B) Basal and post-forskolin net Na
+ flux rates in the three different groups. Whereas Na
+ absorption was
completely abolished in group II, active Na
+ absorption was only partially inhibited in group III. Only in the control group I could an inhibition of Na
+
absorption by forskolin be observed, indicating normal regulation (n=6/group). *p,0.05
doi:10.1371/journal.pone.0001308.g006
EcN Inhibits Leaky Gut
PLoS ONE | www.plosone.org 7 December 2007 | Issue 12 | e1308permeability, and altered ZO-1 mRNA expression levels. It can be
speculated that the rise of ZO-1 expression results in a reduced
intestinal permeability by an enhanced junctional complex or a
reinforced interaction of the junctional complex with actin. This
hypothesis is consistent with recently published data regarding the
antrum mucosal protein (AMP)-18 that ameliorates DSS colitis in
mice and also enhances accumulation of occludin and ZO-1 in TJ
domains in vitro [55]. Since AMP peptide also prevented a fall in
transepithelial resistance during disruption of actin filaments and
stabilized the perijunctional actin during oxidant injury, it has
been suggested that AMP-18 could protect the intestinal mucosal
barrier by acting on specific TJ proteins and stabilizing
perijunctional actin [55]. Using another murine colitis model,
administration of n-3 polyunsaturated fatty acids resulted not only
in reduced pathological scores but also an increase of ZO-1
protein expression [56].
The present study clearly demonstrates that EcN specifically up-
regulates ZO-1 mRNA expression in IECs in vivo. Together with
the influence of EcN on intestinal permeability and an enhanced
ZO-1 expression under pathological conditions, it can be
speculated that EcN augments mucosal barrier function. These
in vivo results corroborate the in vitro findings from other groups by
demonstrating that probiotic EcN plays an important role in the
maintenance of intestinal barrier function. An improved barrier
integrity elicited by EcN is an appealing explanation for the
success of this probiotic in the therapy of UC and could be an
important aspect in treating further human intestinal disorders,
including HIV-associated diarrhea.
ACKNOWLEDGMENTS
We thank further Lothar Gro ¨be for FACS sorting, Marco Metzger for
performing immunohistochemistry and Silvia Prettin for technical support
as well as Anna Smoczek and Ina Ko ¨hn for animal care. The authors also
gratefully acknowledge Michael J. Schubert for critically reading the
manuscript.
Author Contributions
Conceived and designed the experiments: SU US JB FG AW. Performed
the experiments: SU AS UD RE AB. Analyzed the data: SU AW.
Contributed reagents/materials/analysis tools: SS AF SU WH DB GR.
Wrote the paper: SU FG AW.
REFERENCES
1. Farquhar MG, Palade GE (1963) Junctional complexes in various epithelia.
J Cell Biol 17: 375–412.
2. Kapembwa MS, Fleming SC, Sewankambo N, Serwadda D, Lucas S, et al.
(1991) Altered small-intestinal permeability associated with diarrhoea in human-
immunodeficiency-virus-infected Caucasian and African subjects. Clin Sci
(Lond) 81: 327–334.
3. Rene E, Marche C, Regnier B, Saimot AG, Vilde JL, et al. (1989) Intestinal
infections in patients with acquired immunodeficiency syndrome. A prospective
study in 132 patients. Dig Dis Sci 34: 773–780.
4. Smith PD, Lane HC, Gill VJ, Manischewitz JF, Quinnan GV, et al. (1988)
Intestinal infections in patients with the acquired immunodeficiency syndrome
(AIDS). Etiology and response to therapy. Ann Intern Med 108: 328–333.
5. Stevenson BR, Siliciano JD, Mooseker MS, Goodenough DA (1986)
Identification of ZO-1: a high molecular weight polypeptide associated with
the tight junction (zonula occludens) in a variety of epithelia. J Cell Biol 103:
755–766.
6. Wittchen ES, Haskins J, Stevenson BR (1999) Protein interactions at the tight
junction. Actin has multiple binding partners, and ZO-1 forms independent
complexes with ZO-2 and ZO-3. J Biol Chem 274: 35179–35185.
7. Ma TY, Boivin MA, Ye DM, Pedram A, Said HM (2005) Mechanism of tumor
necrosis factor-alpha modulation of Caco-2 intestinal epithelial tight junction
barrier: Role of myosin light chain kinase protein expression. Am J Physiol
Gastrointest Liver Physiol 288: G422–G430.
8. Wang F, Graham WV, Wang Y, Witkowski ED, Schwarz BT, et al. (2005)
Interferon-gamma and tumor necrosis factor-alpha synergize to induce intestinal
epithelial barrier dysfunction by up-regulating myosin light chain kinase
expression. Am J Pathol 166: 409–419.
9. Gumbiner B, Lowenkopf T, Apatira D (1991) Identification of a 160-kDa
polypeptide that binds to the tight junction protein ZO-1. Proc Natl Acad
Sci U S A 88: 3460–3464.
10. Zyrek AA, Cichon C, Helms S, Enders C, Sonnenborn U, et al. (2007)
Molecular mechanisms underlying the probiotic effects of Escherichia coli Nissle
1917 involve ZO-2 and PKCzeta redistribution resulting in tight junction and
epithelial barrier repair. Cell Microbiol 9: 804–816.
11. Havenaar R, Huis in ’t Veld JHJ (1992) Probiotics: a general view. In:
Wood BJB, ed (1992) The Lactic Acid Bacteria. New York: Chapman & Hall. pp
209–224.
12. Kruis W, Schutz E, Fric P, Fixa B, Judmaier G, et al. (1997) Double-blind
comparison of an oral Escherichia coli preparation and mesalazine in maintaining
remission of ulcerative colitis. Aliment Pharmacol Ther 11: 853–858.
13. Kruis W, Fric P, Pokrotnieks J, Lukas M, Fixa B, et al. (2004) Maintaining
remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as
effective as with standard mesalazine. Gut 53: 1617–1623.
14. Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon ATR (1999)
Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative
colitis: a randomised trial. Lancet 354: 635–639.
15. Westendorf AM, Gunzer F, Deppenmeier S, Tapadar D, Hunger JK, et al.
(2005) Intestinal immunity of Escherichia coli NISSLE 1917: a safe carrier for
therapeutic molecules. FEMS Immunol Med Microbiol 43: 373–384.
16. Henker J, Laass M, Blokhin BM, Bolbot YK, Maydannik VG, et al. (2007) The
probiotic Escherichia coli strain Nissle 1917 (EcN) stops acute diarrhoea in infants
and toddlers. Eur J Pediatr 166: 311–318.
17. Dotan I, Rachmilewitz D (2005) Probiotics in inflammatory bowel disease:
possible mechanisms of action. Curr Opin Gastroenterol 21: 426–430.
18. Sartor RB (2004) Therapeutic manipulation of the enteric microflora in
inflammatory bowel diseases: Antibiotics, probiotics, and prebiotics. Gastroen-
terology 126: 1620–1633.
19. Resta-Lenert S, Barrett KE (2003) Live probiotics protect intestinal epithelial
cells from the effects of infection with enteroinvasive Escherichia coli (EIEC). Gut
52: 988–997.
20. Bleich A, Sundberg JP, Smoczek A, von Wasielewski R, de Buhr MF, et al. (2007)
Sensitivity to Escherichia coli Nissle 1917 in mice is dependent on environment and
genetic background. Int J Exp Pathol Nov 13: Epub ahead of print.
21. Gunzer F, Hennig-Pauka I, Waldmann KH, Mengel M (2003) Gnotobiotic
piglets as an animal model for oral infection with O157 and non-O157 serotypes
of STEC. Methods Mol Med 73: 307–327.
22. Grabig A, Paclik D, Guzy C, Dankof A, Baumgart DC, et al. (2006) Escherichia
coli strain Nissle 1917 ameliorates experimental colitis via toll-like receptor 2-
and toll-like receptor 4-dependent pathways. Infect Immun 74: 4075–4082.
Figure 7. Permeability to Evans Blue in the colon of DSS treated
(group II), DSS+EcN (group III) treated mice and healthy controls
(group I). The graph shows a significant increase in Evans Blue uptake
into the colonic mucosa of group II mice and a strong reduction in
Evans Blue uptake in group III mice to almost normal values (n=6/
group). ***p,0.001
doi:10.1371/journal.pone.0001308.g007
EcN Inhibits Leaky Gut
PLoS ONE | www.plosone.org 8 December 2007 | Issue 12 | e130823. Rogler G, Daig R, Aschenbrenner E, Vogl D, Schlottmann K, et al. (1998)
Establishment of long-term primary cultures of human small and large intestinal
epithelial cells. Lab Invest 78: 889–890.
24. Spyridonidis A, Schmitt-Graff A, Tomann T, Dwenger A, Follo M, et al. (2004)
Epithelial tissue chimerism after human hematopoietic cell transplantation is a
real phenomenon. Am J Pathol 164: 1147–1155.
25. Schu ¨rmann G, Bru ¨wer M, Klotz A, Schmid KW, Senninger N, et al. (1999)
Transepithelial transport processes at the intestinal mucosa in inflammatory
bowel disease. Int J Colorectal Dis 14: 41–46.
26. Ivanov AI, Nusrat A, Parkos CA (2004) The epithelium in inflammatory bowel
disease: potential role of endocytosis of junctional proteins in barrier disruption.
Novartis Found Symp 263: 115–124.
27. Nejdfors P, Wang Q, Ekelund M, Westrom BR, Jansson O, et al. (1998)
Increased colonic permeability in patients with ulcerative colitis: An in vitro
study. Scand J Gastroenterol 33: 749–753.
28. Wyatt J, Vogelsang H, Hubl W, Waldhoer T, Lochs H (1993) Intestinal
permeability and the prediction of relapse in Crohn’s disease. Lancet 341:
1437–1439.
29. Schultz M, Strauch UG, Linde HJ, Watzl S, Obermeier F, et al. (2004)
Preventive effects of Escherichia coli strain Nissle 1917 on acute and chronic
intestinal inflammation in two different murine models of colitis. Clin Diagn Lab
Immunol 11: 372–378.
30. Podolsky DK (2002) Inflammatory bowel disease. N Engl J Med 347: 417–429.
31. Jepson MA, Collares-Buzato CB, Clark MA, Hirst BH, Simmons NL (1995)
Rapid disruption of epithelial barrier function by Salmonella typhimurium is
associated with structural modification of intercellular junctions. Infect Immun
63: 356–359.
32. Jepson MA, Schlecht HB, Collares-Buzato CB (2000) Localization of
dysfunctional tight junctions in Salmonella enterica serovar typhimurium-infected
epithelial layers. Infect Immun 68: 7202–7208.
33. Philpott DJ, McKay DM, Mak W, Perdue MH, Sherman PM (1998) Signal
transduction pathways involved in enterohemorrhagic Escherichia coli-induced
alterations in T84 epithelial permeability. Infect Immun 66: 1680–1687.
34. McCarthy J, O’Mahony L, O’Callaghan L, Sheil B, Vaughan EE, et al. (2003)
Double blind, placebo controlled trial of two probiotic strains in interleukin 10
knockout mice and mechanistic link with cytokine balance. Gut 52: 975–980.
35. Rachmilewitz D, Katakura K, Karmeli F, Hayashi T, Reinus C, et al. (2004)
Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics
in murine experimental colitis. Gastroenterology 126: 520–528.
36. Schultz M, Veltkamp C, Dieleman LA, Grenther WB, Wyrick PB, et al. (2002)
Lactobacillus plantarum 299V in the treatment and prevention of spontaneous
colitis in interleukin-10-deficient mice. Inflamm Bowel Dis 8: 71–80.
37. Kunzelmann K, Mall M (2002) Electrolyte transport in the mammalian colon:
Mechanisms and implications for disease. Physiol Rev 82: 245–289.
38. Seidler U, Lenzen H, Cinar A, Tessema T, Bleich A et al (2006) Molecular
mechanisms of disturbed electrolyte transport in intestinal inflammation.
Ann N Y Acad Sci 1072: 262–275.
39. Clayburgh DR, Barrett TA, Tang YM, Meddings JB, Van Eldik LJ, et al. (2005)
Epithelial myosin light chain kinase-dependent barrier dysfunction mediates T
cell activation-induced diarrhea in vivo. J Clin Invest 115: 2702–2715.
40. Schmitz H, Barmeyer C, Fromm M, Runkel N, Foss HD, et al. (1999) Altered
tight junction structure contributes to the impaired epithelial barrier function in
ulcerative colitis. Gastroenterology 116: 301–309.
41. Stockmann M, Fromm M, Schmitz H, Schmidt W, Riecken EO, et al. (1998)
Duodenal biopsies of HIV-infected patients with diarrhoea exhibit epithelial
barrier defects but no active secretion. AIDS 12: 43–51.
42. Schmitz H, Rokos K, Florian P, Gitter AH, Fromm M, et al. (2002)
Supernatants of HIV-infected immune cells affect the barrier function of human
HT-29/B6 intestinal epithelial cells. AIDS 16: 983–991.
43. Levine MM, Kaper JB, Herrington D, Losonsky G, Morris JG, et al. (1988)
Volunteer studies of deletion mutants of Vibrio cholerae O1 prepared by
recombinant techniques. Infect Immun 56: 161–167.
44. Fasano A, Baudry B, Pumplin DW, Wasserman SS, Tall BD, et al. (1991) Vibrio
cholerae produces a second enterotoxin, which affects intestinal tight junctions.
Proc Natl Acad Sci U S A 88: 5242–5246.
45. Wu Z, Milton D, Nybom P, Sjo A, Magnusson KE (1996) Vibrio cholerae
hemagglutinin/protease (HA/protease) causes morphological changes in
cultured epithelial cells and perturbs their paracellular barrier function. Microb
Pathog 21: 111–123.
46. Wu Z, Nybom P, Magnusson KE (2000) Distinct effects of Vibrio cholerae
haemagglutinin/protease on the structure and localization of the tight junction-
associated proteins occludin and ZO-1. Cell Microbiol 2: 11–17.
47. Fasano A, Uzzau S (1997) Modulation of intestinal tight junctions by Zonula
occludens toxin permits enteral administration of insulin and other macromol-
ecules in an animal model. J Clin Invest 99: 1158–1164.
48. Hollander D (1999) Intestinal permeability, leaky gut, and intestinal disorders.
Curr Gastroenterol Rep 1: 410–416.
49. Meddings JB (1997) Intestinal permeability in Crohn’s disease. Aliment
Pharmacol Ther 11: 45–53.
50. Barmeyer C, Harren M, Schmitz H, Heinzel-Pleines U, Mankertz J, et al. (2004)
Mechanisms of diarrhea in the interleukin-2-deficient mouse model of colonic
inflammation. Am J Physiol Gastrointest Liver Physiol 286: G244–G252.
51. Parassol N, Freitas M, Thoreux K, Dalmasso G, Bourdet-Sicard R, et al. (2005)
Lactobacillus casei DN-114 001 inhibits the increase in paracellular permeability of
enteropathogenic Escherichia coli-infected T84 cells. Res Microbiol 156: 256–262.
52. Alberda C, Gramlich L, Meddings J, Field C, McCargar L, et al. (2007) Effects
of probiotic therapy in critically ill patients: a randomized, double-blind,
placebo-controlled trial. Am J Clin Nutr 85: 816–823.
53. Oshitani N, Watanabe K, Nakamura S, Fujiwara Y, Higuchi K, et al. (2005)
Dislocation of tight junction proteins without F-actin disruption in inactive
Crohn’s disease. Int J Mol Med 15: 407–410.
54. Resta-Lenert S, Smitham J, Barrett KE (2005) Epithelial dysfunction associated
with the development of colitis in conventionally housed mdr1a(-/-) mice.
Am J Physiol Gastrointest Liver Physiol 289: G153–G162.
55. Walsh-Reitz MM, Huang EF, Musch MW, Chang EB, Martin TE, et al. (2005)
AMP-18 protects barrier function of colonic epithelial cells: role of tight junction
proteins. Am J Physiol Gastrointest Liver Physiol 289: G163–G171.
56. Whiting CV, Bland PW, Tarlton JE (2005) Dietary n-3 polyunsaturated fatty
acids reduce disease and colonic proinflammatory cytokines in a mouse model of
colitis. Inflamm Bowel Dis 11: 340–349.
EcN Inhibits Leaky Gut
PLoS ONE | www.plosone.org 9 December 2007 | Issue 12 | e1308